12:00 AM
Oct 25, 2010
 |  BC Week In Review  |  Clinical News  |  Clinical Results

LibiGel testosterone: Interim Phase III data

Interim data from about 2,300 evaluable women in a double-blind, placebo-controlled, international Phase III safety trial evaluating transdermal LibiGel for 12 months showed that the rates of cardiovascular and breast cancer events were 0.65% and 0.32%, respectively, after about 10.5 months of...

Read the full 187 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >